SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT
23.08.2024
GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY
14.08.2024
HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.
02.07.2024
AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
11.06.2024
Annual General Meeting completed
10.05.2024
DISCLOSURE OF LARGE SHAREHOLDING
05.04.2024
UPDATED COMPANY PRESENTATION
21.03.2024
FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT
09.02.2024
HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity
06.02.2024
SHARE CAPITAL INCREASE REGISTERED
09.01.2024